Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × sargramostim × Clear all

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05455658 2025-10-24

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Phase 1/2 Completed

26 enrolled 14 charts

BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00640861 2018-10-31

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms